ESR1 and breast cancer: Accordingly, growing ER+ breast cancer cells in the absence of estradiol (E2) or ERα knock-down (KD) strongly reduces p53 mRNA and protein levels, finally impairing doxorubicin-induced DNA damage-dependent apoptosis [22].